Forskning ved Københavns Universitet - Københavns Universitet


A new adjuvant enhances the protection of the commercial influenza vaccine in the ferret model

Publikation: KonferencebidragPosterForskning


  • Cyril Jean-Marie Martel
  • Trine Hammer Jensen
  • Lars P. Nielsen
  • Birgitte Viuff
  • Else-Marie Agger
  • Merete Blixenkrone-Møller
  • Peter Andersen
  • Aasted, Bent
DDA-TDB is a cationic liposome-based adjuvant known to produce a very substantial CMI and at the same time a strong humoral response, desirable for a high number of disease targets. We tested the effect of this adjuvant when combined to a commercially available inactivated influenza vaccine. When challenged with H1N1 A/New Caledonia/20/99, ferrets immunized with the adjuvanted vaccine displayed a much stronger humoral response and lower viral titers than the ones that received only the regular vaccine. Gamma-interferon production, assessed by both RT-PCR and flow cytometry, and pathology studies on the upper and lower respiratory tract confirmed those findings. This study indicates that DDA/TDB has a strong potential to be used as an adjuvant for inactivated influenza vaccines.
Antal sider1
StatusUdgivet - 2007
BegivenhedInternational Veterinary Immunology Symposium - Ouro Preto, Brasilien
Varighed: 15 aug. 200719 aug. 2007
Konferencens nummer: 8


KonferenceInternational Veterinary Immunology Symposium
ByOuro Preto

Bibliografisk note

Sider: 77

Antal downloads er baseret på statistik fra Google Scholar og

Ingen data tilgængelig

ID: 8107454